In conclusion, this is the first in vitro study to show that minocycline and doxycycline have a significant inhibitory effect in CD4+ T and NKT cell producing IFN-γ and/or IL-17 in patients with MS (naïve or under treatment). Here, IL17A is linked to myeloid sarcoma.